Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Allergic Asthma
Interventions
BIOLOGICAL

FB825

A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).

OTHER

Placebo

Formulation buffer

Trial Locations (16)

Unknown

RECRUITING

Chiayi Chang Gung Memorial Hospital, Chiayi City

RECRUITING

Kaohsiung Chang Gung Medical Foundation, Kaohsiung City

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

RECRUITING

Far Eastern Memorial Hospital, New Taipei City

RECRUITING

China Medical University Hospital, Taichung

RECRUITING

Taichung Venterans General Hospital, Taichung

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

Linkou Chang Gung Memorial Hospital, Taipei

RECRUITING

MacKay Memorial Hospital, Taipei

RECRUITING

Ministry of Health and Welfare Shuang-Ho Hospital, Taipei

RECRUITING

National Taiwan University Hospital Hsin-Chu Branch, Taipei

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Taipei Medical University Hospital, Taipei

RECRUITING

Taipei Municipal Wanfang Hospital, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

Tri-Service General Hospital, Taipei

Sponsors
All Listed Sponsors
collaborator

Microbio Shanghai Co., Ltd.

UNKNOWN

lead

Oneness Biotech Co., Ltd.

INDUSTRY